News Focus
News Focus
Post# of 257313
Next 10
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

Re: jq1234 post# 113057

Monday, 01/24/2011 6:08:42 PM

Monday, January 24, 2011 6:08:42 PM

Post# of 257313

AMGN’s acquisition of BioVex is quite high-risk…

In addition to the program risk stemming from the novel MoA, there is some execution risk in the melanoma setting stemming from the unusual primary endpoint of the phase-3 trial:

http://clinicaltrials.gov/ct2/show/NCT00769704

Primary Outcome Measure: Achieving a statistically significant improvement in durable response rate, defined as the rate of CR or PR lasting continuously for 6 or more months, as compared to control therapy.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today